Research
Hormonal
In drug-naive patients with diabetes, initiating GLP-1 RA as first-line therapy reduces the 1-year risk of requiring additional glucose-lowering medication compared to metformin, with no significant difference in adherence rates.
For patients with diabetes, GLP-1 RA is more effective than metformin at preventing the need for extra diabetes medications over one year, with similar adherence rates. This makes GLP-1 RA a strong first-line option for diabetes management.
GoodSupportsHIGH confidence
In patients with diabetes, GLP-1 RA was associated with an RR of 0.67 (95% CI: 0.37–0.98, p-value = 0.037)... For patients with diabetes, this RR was 0.88 (95% CI: 0.70–1.06, p = 0.185)
Why this rating
Large nationwide cohort study with rigorous matching and adjustment.
Source
Comparing Glucagon‐like peptide‐1 receptor agonists versus metformin in drug‐naive patients: A nationwide cohort study
Kathrine Kold Sørensen et al. · Journal of Diabetes · 2024
DOI 10.1111/1753-0407.70000
cohort · n=3556Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In drug-naive patients with prediabetes, initiating GLP-1 RA as first-line therapy significantly reduces the 1-year risk of requiring additional glucose-lowering medication compared to metformin, but is associated with a significantly higher risk of treatment nonadherence.Good
- First-line GLP-1 RA initiation is associated with greater HbA1c reduction compared to metformin in both patients with prediabetes and diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →